Smoking Cessation Interventions for Lung Cancer Screening Patients
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine which of four methods best helps smokers quit for at least six months. Researchers will divide participants into groups to receive different types of support, including financial incentives, a mobile health application, and cost-free access to certain medications. The trial seeks current smokers who have undergone lung cancer screening and are considered underserved, such as those with lower income or limited access to healthcare. Participants must have a cell phone capable of receiving texts or accessing the internet. As an unphased trial, this study offers a unique opportunity to explore innovative methods for quitting smoking and improving health outcomes.
Do I need to stop taking my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that offering money can safely and effectively help people quit smoking. One study found that financial rewards increased the chances of quitting by about 1.5 times without major safety issues.
Regarding mobile health (mHealth) apps, research indicates they can assist in quitting smoking. Although some concerns exist about the safety of health apps in general, most studies suggest they are safe for users. These apps can track progress and provide support. It is advisable to read app reviews and choose ones from trusted sources.
Both financial incentives and mHealth apps aim to make quitting smoking easier and safer. They have been widely studied, and while no method is completely risk-free, these tools are generally well-tolerated by most people.12345Why are researchers excited about this trial?
Researchers are excited about these treatments because they incorporate innovative methods to help people quit smoking, especially for those undergoing lung cancer screening. Unlike standard approaches that often rely solely on advice and resources, these treatments use financial incentives and mobile health applications to motivate smokers. One unique feature is the use of episodic future thinking (EFT) through the FutureMe intervention, which encourages individuals to envision their future selves, helping to reduce the tendency to prioritize immediate rewards over long-term health benefits. Additionally, the removal of financial barriers by providing free access to nicotine replacement therapies and reimbursement for smoking cessation medications makes these treatments more accessible and potentially more effective.
What evidence suggests that this trial's treatments could be effective for smoking cessation?
Research has shown that offering money can significantly increase the number of people who quit smoking. For instance, one study found that financial rewards helped more people stop smoking at a low cost per quitter. In this trial, some participants will receive financial incentives as part of their treatment arm. Mobile health apps also show promise; studies have shown they can triple the likelihood of quitting smoking within three to six months compared to older methods. These apps are easy to use and have proven effective in helping people stop smoking. Participants in this trial may receive a mobile health application as part of their treatment arm. Both financial incentives and mobile apps offer solid support for quitting smoking, making them effective options for helping smokers stay smoke-free.12367
Who Is on the Research Team?
Scott D Halpern, MD PhD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for underserved adult smokers referred for lung cancer screening. Participants must be 18+, have a cell phone with text or internet, and meet at least one of these: Black, Hispanic, rural resident, or low income. They should smoke at least 1 cigarette per day and not use e-cigarettes.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment and Pre-Quit Preparation
Participants enroll with opt-out consent and prepare for their quit date using the NIH-funded Way to Health online research portal
Treatment
Participants receive one of four interventions to promote smoking cessation, including enhanced usual care, financial incentives, and mobile health applications
Follow-up
Participants are monitored for relapse rates and health-related quality of life at 12 months
What Are the Treatments Tested in This Trial?
Interventions
- Financial Incentives
- Mobile Health Application
- Removal of Financial Barriers
Trial Overview
The study compares four ways to help people quit smoking: removing cost barriers to quitting aids, offering money rewards for staying smoke-free, using a mobile app designed to support quitting efforts. The goal is to see which method helps maintain no smoking for six months.
How Is the Trial Designed?
4
Treatment groups
Active Control
Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.
Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
University of Pennsylvania
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborator
Published Research Related to This Trial
Citations
Financial Incentives for Smoking Cessation Among ...
This randomized clinical trial compares the long-term effects of adjunctive, low-cost financial incentives plus usual care for smoking cessation.
Comparing the Effectiveness of Four Ways To Promote ...
Results from this study can help lung cancer screening programs choose the best ways to help people quit smoking.
Reducing Lung Cancer Mortality by Providing Smoking ...
SCS delivered in the LCS setting can considerably reduce lung cancer mortality, with the potential to reduce global, racial, economic, and geographic ...
Global Insights into Smoking Cessation in Lung Cancer ... - ILCN
Smoking cessation interventions are a critical component of lung cancer screening (LCS) programs, as they have been shown to reduce smoking-related risks and ...
Paying Low-Income Smokers to Quit? The Cost ...
The ICER of the financial incentives intervention was $2316 (95% confidence interval $1582–$4270) per additional person who quit. The study ICER compares ...
Effects of large financial incentives on motivation to quit ...
A Cochrane meta-analysis of randomized trials concluded that financial incentives increase smoking cessation rates by a factor of 1.49, and that this effect is ...
Small Financial Incentives to Promote Smoking Cessation
Participants will receive a payment for completion of the in-person assessments, which will take approximately 40 minutes to complete. Saliva cotinine will also ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.